Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

How will the upcoming OX2R agonist data readouts affect CENTA's valuation and price target? What are the specific financial results (revenue, net loss, cash burn) for Q2 2025 and how do they compare to the same quarter last year? Did the company provide any updated guidance for the full year 2025, and how does it compare to consensus estimates? What is the current cash and liquid assets position, and how many months of runway does it provide under current burn rates? Are there any new partnership or licensing agreements disclosed in the release that could impact future revenue streams? How does CENTA's OX2R franchise progress compare to other companies developing orexin receptor agonists or competing sleep/neurology pipelines? What milestones (e.g., IND filing, Phase 1/2 trial start) are expected for the OX2R program, and what are the timelines? Did the company disclose any changes to its R&D spending or reallocation of resources that could affect future development timelines? Are there any regulatory hurdles or upcoming FDA/EMA interactions that could impact the timeline for data readouts? How does the market’s sentiment (60) align with analyst expectations, and is there a potential for a short‑term price move? What are the potential upside and downside risks associated with the upcoming data readouts for the OX2R franchise? How does the current valuation (P/E, EV/EBITDA, market cap) compare to peer biotech companies focusing on similar mechanisms?